6790 Federal Register / Vol. 62, No. 30 / Thursday, February 13, 1997 / Notices

Dated: February 4, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–3528 Filed 2–12–97; 8:45 am]

BILLING CODE 4140–01–M

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The invention listed below is

owned by an agency of the U.S.

Government and is available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for U.S. companies and may also be

available for licensing.

ADDRESSES: Licensing information and a

copy of the U.S. patent application

referenced below may be obtained by

contacting Cindy K. Fuchs, J.D., at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804 (telephone 301/

496–7735 ext 232; fax 301/402–0220). A

signed Confidential Disclosure

Agreement will be required to receive a

copy of the patent application.

The CCHC Zinc Fingers of the

Retroviral Nucleocapsid Protein

Comprises a New Target Useful in

Identification and Evaluation of AntiHIV Therapeutics

L Henderson, L Arthur, W Rice, and A

Rein (NCI)

Serial No. 08/379,420 filed January 27,

1995

HIV–1 contains domains known as

‘‘CCHC zinc fingers’’ in the retroviral

nucleocapsid (NC) protein.

Nucleocapsid CCHC zinc fingers are

highly conserved throughout nearly all

retroviruses, and are sequences of 14

amino acids with four invariant

residues, Cys(X)2Cys(X)4His(X)4Cys, that

chelate zinc and perform essential

functions in viral infectivity. HIV–1 NC

has two CCHC zinc fingers, both of

which are necessary for infectivity.

Many compounds that disrupt the

CCHC zinc fingers also inactivate HIV–

1 by preventing the initiation of reverse

transcription and by blocking

production of infectious virus from

previously infected cells by disruption

of Gag processing. Compounds with this

activity may be useful for developing

new types of antiretroviral drugs. The

invention concerns antiretroviral

compounds that disrupt the CCHC zinc

fingers and assays for identifying such

compounds. The invariant nature of

retroviral zinc fingers extends the

usefulness of these compounds to other

retroviruses. Thus these assays are also

useful for screening compounds

effective against adult T cell leukemia,

tropical spastic paraparesis caused by

HTLV–1 and HTLV–II, feline leukemia

virus, feline immunodeficiency virus,

equine infectious virus, and lentivirus

infections in other animals. This

invention is available for licensing on

an exclusive or non-exclusive basis.

(Portfolios: Infectious Diseases—

Therapeutics, anti-virals, AIDS; Infectious

Diseases—Research Materials)

Dated: February 4, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–3529 Filed 2–12–97; 8:45 am]

BILLING CODE 4140–01–M

National Library of Medicine; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C., Appendix 2), notice

is hereby given of the following

National Library of Medicine Special

Emphasis Panel (SEP) meeting:

Name of SEP: National Library of Medicine

Special Emphasis Panel.

Date: February 10, 1997.

Time: 11:00 a.m.

Place: Conference Call, 8600 Rockville

Pike, Bldg. 38A, Rm. 5S–522, Bethesda,

Maryland 20894, 301/496–4221.

Contact: Dr. Roger W. Dahlen, Chief,

Biomedical Information Support Branch, EP,

8600 Rockville Pike, Bldg. 38A, Rm. 5S–522,

Bethesda, Maryland 20894, 301/496–4221.

Purpose/Agenda: To evaluate and review

Fellowship grant applications. The meeting

will be closed in accordance with the

provisions set forth in secs. 552b(c)(4) and

552b(c)(6), Title 5, U.S.C. Applications and/

or proposals and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the applications and/or

proposals, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy. This notice is being

published less than 15 days prior to the

meeting due to the urgent need to meet

timing limitations imposed by the review and

funding cycle.

(Catalog of Federal Domestic Assistance

Program No. 93–879—Medical Library

Assistance, National Institutes of Health)

Dated: February 7, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–3631 Filed 2–10–97; 2:31 pm]

BILLING CODE 4140–01–M

Division of Research Grants; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Division

of Research Grants Special Emphasis

Panel (SEP) meetings:

Purpose/Agenda: To review individual

grant applications.

Name of SEP: Chemistry and Related

Sciences.

Date: March 6–8, 1997.

Time: 8:00 a.m.

Place: Redlion Inn, Richland, Washington.

Contact Person: Dr. Marjam Behar,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5218, Bethesda,

Maryland 20892, (301) 435–1180.

Name of SEP: Clinical Sciences.

Date: March 20, 1997.

Time: 8:00 a.m.

Place: Holiday Inn, Chevy chase,

Maryland.

Contact Person: Ms. Josephine Pelham,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4106, Bethesda,

Maryland 20892, (301) 435–1786.

Name of SEP: Biological and Physiological

Sciences.

Date: March 20, 1997.

Time: 3:00 p.m.

Place: NIH, Rockledge 2, Room 4144,

Telephone Conference.

Contact Person: Dr. Paul Strudler,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4144, Bethesda,

Maryland 20892, (301) 435–1716.

Name of SEP: Microbiological and

Immunological Sciences.

Date: March 24–25, 1997.

Time: 8:30 a.m.

Place: Doubletree Hotel, Rockville,

Maryland.

Contact Person: Dr. Garrett Keefer,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4190, Bethesda,

Maryland 20892, (301) 435–1152.

Name of SEP: Chemistry and Related

Sciences.

Date: April 14–16, 1997.

Time: 4:00 p.m.

Place: Hampton Inn, Urbana, Illinois.

Contact Person: Dr. Nancy Lamontagne,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4170, Bethesda,

Maryland 20892, (301) 435–1726.

Name of SEP: Clinical Sciences.

Date: April 18, 1997.

Time: 11:00 a.m.

Place: NIH, Rockledge 2, Room 4126,

Telephone Conference.

Contact Person: Dr. Jerrold Fried, Scientific

Review Administrator, 6701 Rockledge Drive,

Room 4126, Bethesda, Maryland 20892, (301)

435–1777.